Compound ID | 165
Synonym(s): MRX-4/MRX-1
Class: Oxazolidinone
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Protein synthesis inhibitor |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus sp. ABSSI infections |
| Institute where first reported: | MicuRx Pharmaceuticals, USA |
| Year first mentioned: | 2014 |
| Highest developmental phase: | Approved in China in 2021 |
| Development status: | Approved |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/25184541 |
| Guide to Pharmacology: | contezolid |
| Citations: |
|